Genomics · Genetic Reports · Precision Wellness
Urinary Tract Health
Personalized Genetic Report
Urinary Tract Health
Accession #: MRW-26-660E57
Report type: Full Report
Report status: FINAL
Specimen and client information
Specimen type
Buccal (cheek) swab
Date reported
29 July 2026
Panel
Urinary Tract Health
What this report covers
Urinary Tract Health
About this report
This report reads your DNA and sorts every result into one of five plain-language groups, so you can see at a glance what deserves attention and what does not. Nothing here is a diagnosis. A flagged result means your genetics place you above or below the average person for that trait — a reason to ask a question, not a reason to worry.
What each result group means
Worth a conversation with your doctor
These came back with a higher genetic predisposition than most people. That is not a diagnosis — it means these are the ones worth raising at your next appointment.
Running above the typical range
Your genetics point to these sitting higher than average. Often useful to know, sometimes worth monitoring.
Running below the typical range
Your genetics point to these sitting lower than average. Same idea — context, not alarm.
Working in your favour
Good news. Your genetics look protective or better than average here.
In line with most people
Nothing unusual. These were tested and came back typical — worth having on record.
Your results at a glance
How to read this. A result being flagged does not mean you have a condition — it means your genetics put you above or below the average person for that trait. Of the 12 results here, 7 came back worth discussing with a clinician and 1 came back in your favour. Bring this document to your appointment.
Worth a conversation with your doctor (7)These came back with a higher genetic predisposition than most people. That is not a diagnosis — it means these are the ones worth raising at your next appointment.
From your Urinary Tract Health report
AUrinary Tract Infections
More likely
Higher predisposition than 97% of people
SLC26A5 rs148099564 CC · ADAL rs140427966 AA · ADAL rs146906133 TT · TRIM69 rs181576645 AA · CTDSPL2 rs182345433 AA · SCIN rs13243276 CC · FRA10AC1 rs7091068 TT · PSCA rs2976388 AA
AProstate Cancer
More likely
Higher predisposition than 94% of people
FSTL5 rs7691481 CC · FGF9 rs781386326 GG · GINS4 rs56336841 CC · KCND2 rs73429913 CC · TNFSF11 rs532873142 CC
AProstate Inflammation
More likely
Higher predisposition than 94% of people
GATA5 rs200383755 GG · GATA3 rs17144046 AG · NCL rs62199052 GC · MACROH2A1 rs677394 CC · H4C13 rs200476 AA · GCLC rs534957 CG · STARD4 rs10054105 TT · GATA6 rs9958656 TT
AOveractive Bladder
Worse
Higher predisposition than 93% of people
ADAM15 rs1218596 CC · WNT5A rs13059018 CG · PHACTR1 rs34998271 GG · C1ORF127 rs77414117 AA · COL11A1 rs181487399 CC
APainful Urination
More likely
Higher predisposition than 88% of people
AUrethra Inflammation
More likely
Higher predisposition than 88% of people
APainful Bladder Syndrome
More likely
Higher predisposition than average
Running above the typical range (0)Your genetics point to these sitting higher than average. Often useful to know, sometimes worth monitoring.
Running below the typical range (0)Your genetics point to these sitting lower than average. Same idea — context, not alarm.
Working in your favour (1)Good news. Your genetics look protective or better than average here.
From your Urinary Tract Health report
FFrequent Urination
Less likely
Lower predisposition than 99% of people
In line with most people (4)Nothing unusual. These were tested and came back typical — worth having on record.
From your Urinary Tract Health report
·Enlarged Prostate
Typical likelihood
In line with the general population · 77th percentile
GATA5 rs200383755 GG · GATA3 rs17144046 AG · MACROH2A1 rs677394 CC · H4C13 rs200476 AA · GCLC rs534957 CG · STARD4 rs10054105 TT · GATA6 rs9958656 TT · TBX5 rs2555019 CC
·Night Peeing
Typical likelihood
In line with the general population · 57th percentile
·Urinary Retention
Typical likelihood
In line with the general population · 39th percentile
·Bladder Cancer
Typical likelihood
In line with the general population
TACC3 rs798766 CT · PSCA rs2920281 TT · UGT1A1 rs11892031 AA · P3H2 rs13063162 AA · PSCA rs2294008 TC · MYC rs10094872 AT · NAT2 rs1495741 GA · SOX4 rs76088467 AA
Methodology
Genotyping was performed on DNA extracted from a buccal (cheek) swab using a genome-wide array. Results are derived from peer-reviewed genome-wide association data and, where applicable, published clinical guidelines. Each report was scored independently against its own reference set. Percentile figures describe where your result sits relative to a reference population.
Limitations
This is a laboratory-developed test. It has not been cleared or approved by the U.S. Food and Drug Administration. Genotyping does not detect all variants in the genes assessed; the absence of a flagged result does not exclude risk. Predisposition is probabilistic and is modified by environment, lifestyle, ancestry and family history. Results must be interpreted by a qualified healthcare professional and must not be used alone to diagnose, treat, or alter any medication regimen. Marrow does not recommend, prescribe, or dose any supplement or medication.
Performing laboratory & attestation
| Performing laboratory | Gene by Gene, Ltd. |
| Laboratory address | 1445 North Loop West, Suite 760, Houston, TX 77008 |
| CLIA certification | CLIA #45D1102202 |
| CAP accreditation | CAP #7212851 · accredited through 7 October 2027 |
| Laboratory Director | Feng Zhou, PhD, MB(ASCP) |
| Specimen type | Buccal (cheek) swab — genomic DNA |
| Accession | MRW-26-660E57 |
| Date reported | 29 July 2026 |
This specimen was tested at Gene by Gene, Ltd., 1445 North Loop West, Suite 760, Houston, TX 77008, under CLIA #45D1102202 and CAP #7212851. Laboratory Director: Feng Zhou, PhD, MB(ASCP). Marrow Health is not a clinical laboratory and does not perform testing; Marrow prepares and delivers this report from data produced by the performing laboratory named above. Report generated 29 July 2026 · Accession MRW-26-660E57 · © 2026 Marrow Health.